Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.
Vaccines preventing HIV-1 infection will likely elicit antibodies that neutralize diverse strains. However, the capacity for lentiviruses to escape broadly neutralizing antibodies (NAbs) is not completely understood, nor is it known whether NAbs alone can control heterologous infection. Here, we determined that convalescent immune plasma from a horse persistently infected with equine infectious anemia virus (EIAV) neutralized homologous virus and several envelope variants containing heterologous principal neutralizing domains (PND). Plasma was infused into young horses (foals) affected with severe combined immunodeficiency (SCID), followed by challenge with a homologous EIAV stock. Treated SCID foals were protected against clinical disease, with complete prevention of infection occurring in one foal. In three SCID foals, a novel neutralization-resistant variant arose that was found to preexist at a low frequency in the challenge inoculum. In contrast, SCID foals infused with nonimmune plasma developed acute disease associated with high levels of the predominant challenge virus. Following transfer to an immunocompetent horse, the neutralization-resistant variant induced a single febrile episode and was subsequently controlled in the absence of type-specific NAb. Long-term control was associated with the presence of cytotoxic T lymphocytes (CTL). Our results demonstrate that immune plasma with neutralizing activity against heterologous PND variants can prevent lentivirus infection and clinical disease in the complete absence of T cells. Importantly, however, rare neutralization-resistant envelope variants can replicate in vivo under relatively broad selection pressure, highlighting the need for protective lentivirus vaccines to elicit NAb responses with increased breadth and potency and/or CTL that target conserved epitopes.
Taylor
Sandra D
SD
Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA.
Leib
Steven R
SR
Carpenter
Susan
S
Mealey
Robert H
RH
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D004859:Equine Infectious Anemia / Q000276:immunology*; D006736:Horses; D007106:Immune Sera / Q000276:immunology*; D004860:Infectious Anemia Virus, Equine / Q000235:genetics / Q000276:immunology*; D016511:Severe Combined Immunodeficiency / Q000150:complications; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D007106:Immune Sera
J Am Vet Med Assoc. 1980 Jun 1;176(11):1250-1
7429919
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11485-9
8524788
Nature. 2007 Sep 6;449(7158):29-30
17805280
Virology. 2007 Jun 20;363(1):156-65
17328936
Vaccine. 2009 Apr 21;27(18):2453-68
19368787
Nature. 2003 Mar 20;422(6929):307-12
12646921
J Infect Dis. 2004 Jun 15;189(12):2167-73
15181562
Virology. 2005 Nov 25;342(2):228-39
16139857
J Gen Virol. 2000 Nov;81(Pt 11):2735-2739
11038386
J Virol. 1999 May;73(5):4009-18
10196297
Clin Immunol. 2001 Nov;101(2):237-47
11683583
J Virol. 1987 Dec;61(12):3783-9
2446008
J Virol. 1997 Dec;71(12):9627-39
9371627
J Immunol. 1997 Apr 15;158(8):3565-9
9103416
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Virol. 2009 Mar;83(6):2743-55
19116253
J Virol. 2006 Jul;80(13):6525-33
16775339
Dev Biol Stand. 1990;72:31-7
2178127
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18514-9
16339909
J Virol. 2004 Sep;78(17):9295-305
15308724
Nature. 2009 Apr 2;458(7238):636-40
19287373
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15105-10
17846425
Transfusion. 2004 Jun;44(6):886-90
15157256
J Virol. 1988 Aug;62(8):3073-6
2839723
J Virol. 2009 Jan;83(2):662-72
18987151
J Virol. 2008 Apr;82(8):3952-70
18256145
J Gen Virol. 2005 Jan;86(Pt 1):139-149
15604441
Am J Vet Res. 1972 Jan;33(1):11-8
4333633
J Virol. 2001 May;75(10):4570-83
11312327
J Gen Virol. 2002 Jun;83(Pt 6):1353-1359
12029150
J Am Vet Med Assoc. 1974 Jan 1;164(1):70-6
4358832
AIDS Res Hum Retroviruses. 2005 Dec;21(12):1057-9
16379610
J Virol. 1986 Jan;57(1):71-80
3001367
Nature. 1998 Jun 18;393(6686):648-59
9641677
Am J Vet Res. 1978 Jun;39(6):1043-7
208432
J Clin Microbiol. 2005 Jan;43(1):406-13
15635002
Antiviral Res. 2004 Mar;61(3):141-51
15168794
Virology. 2005 Aug 15;339(1):110-26
15979679
Virology. 2007 Feb 5;358(1):69-78
16996554
Vet Immunol Immunopathol. 1989 Nov 30;23(1-2):41-9
2559537
AIDS. 2003 Feb 14;17(3):301-9
12556683
J Virol. 1987 Oct;61(10):2956-61
2442410
Nat Rev Immunol. 2004 Mar;4(3):199-210
15039757
Nat Rev Microbiol. 2008 Feb;6(2):143-55
18197170
Vet Immunol Immunopathol. 2008 Jan 15;121(1-2):8-22
17727961
J Gen Virol. 2008 Aug;89(Pt 8):2011-2019
18632973
J Virol. 2004 Apr;78(7):3561-71
15016879
J Virol. 2002 Nov;76(21):10588-97
12368301
Virology. 2003 Sep 1;313(2):537-52
12954220
AIDS Res Hum Retroviruses. 2003 Oct;19(10):923-4
14601590
Virology. 2004 Sep 15;327(1):144-54
15327905
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9918-23
15985554
Virology. 1999 Sep 1;261(2):242-52
10497109
Virology. 2007 Jul 5;363(2):447-53
17355886
J Gen Virol. 1988 Mar;69 ( Pt 3):667-74
3351480
Science. 2009 Nov 20;326(5956):1123-7
19965434
Arch Virol. 1988;98(1-2):91-7
2829799
J Immunol. 1985 Aug;135(2):906-14
2409158
J Virol. 1992 Feb;66(2):732-42
1370556
Nat Med. 1999 Feb;5(2):204-10
9930869
J Virol. 1996 Nov;70(11):7842-50
8892906